{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:08:55Z","timestamp":1777036135927,"version":"3.51.4"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370207"],"award-info":[{"award-number":["82370207"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20240235"],"award-info":[{"award-number":["BK20240235"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To mine adverse drug events (ADEs) following the use of gemtuzumab ozogamicin based on the FDA Adverse Event Reporting System (FAERS), and to provide references for the safety assessment of clinical drug use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We obtained reports of adverse events with gemtuzumab ozogamicin as the main suspect from FAERS from within the first quarter of 2004 and the third quarter of 2024. The reporting odds ratio (ROR), comprehensive standard method (MHRA), Bayesian confidence propagation neural network (BCPNN) and multi-item gamma Poisson shrinker (MGPS) were applied to identify AE signals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2,065 patients were extracted. Screening for adverse drug events identified 238 positive signals. Among these, febrile neutropenia had the highest number of reports, while liver veno-occlusive disease (VOD) had the strongest signal intensity. Notably, our analysis revealed new high-risk signals, including cryptogenic organizing pneumonia (COP) and increased fibrin degradation products, which were not previously highlighted in FAERS analyses. These findings underscore the need for clinicians to closely monitor patients for these emerging risks, particularly in high-risk populations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>By leveraging extensive real-world evidence from FAERS, we detected previously unidentified AEs linked to gemtuzumab ozogamicin via disproportionality analysis. Our results highlight the necessity for clinicians and pharmacists to prioritize the effective handling of this agent\u2019s high-risk AEs, enhance its rational use in clinical settings, and safeguard patient pharmacotherapy. The identification of new signals, such as COP and increased fibrin degradation products, underscores the importance of continuous pharmacovigilance and the need to update clinical guidelines to reflect these emerging risks.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1643780","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:24:58Z","timestamp":1757568298000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety assessment of gemtuzumab ozogamicin: real-world adverse event analysis based on the FDA Adverse Event Reporting System"],"prefix":"10.3389","volume":"12","author":[{"given":"Xuexue","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuoyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yining","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3322\/caac.21873","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.3390\/cancers15113002","article-title":"Paradigm shift in the management of acute myeloid leukemia-approved options in 2023","volume":"15","author":"Premnath","year":"2023","journal-title":"Cancers"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s12185-024-03814-z","article-title":"High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia","volume":"120","author":"Oya","year":"2024","journal-title":"Int J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1158\/1078-0432.Ccr-17-3179","article-title":"FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12885-021-09116-5","article-title":"Targeting CD33 for acute myeloid leukemia therapy","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-019-0175-x","article-title":"Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia","volume":"7","author":"Yu","year":"2019","journal-title":"Biomark Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1558868","DOI":"10.3389\/fphar.2025.1558868","article-title":"A real-world pharmacovigilance analysis of omadacycline in FDA Adverse Event Reporting System (FAERS) database","volume":"16","author":"Shi","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s40364-024-00649-y","article-title":"Global, regional, and national burden of acute myeloid leukemia, 1990\u20132021: a systematic analysis for the global burden of disease study 2021","volume":"12","author":"Zhou","year":"2024","journal-title":"Biomark Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.leukres.2006.07.005","article-title":"Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project","volume":"31","author":"McKoy","year":"2007","journal-title":"Leuk Res"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1160\/th04-09-0621","article-title":"Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population","volume":"93","author":"Sartori","year":"2005","journal-title":"Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1159\/000535500","article-title":"Geriatric assessment in acute myeloid leukemia","volume":"147","author":"Woods","year":"2024","journal-title":"Acta Haematol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00062752-200311000-00010","article-title":"Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment","volume":"10","author":"Wadleigh","year":"2003","journal-title":"Curr Opin Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/jco.2016.71.2513","article-title":"CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III children\u2019s oncology group trial AAML0531","volume":"35","author":"Lamba","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/1074-5521(94)90041-8","article-title":"Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis","volume":"1","author":"Nicolaou","year":"1994","journal-title":"Chem Biol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100004","DOI":"10.1016\/j.bneo.2024.100004","article-title":"Comparison of TP53 mutations in myelodysplasia and acute leukemia suggests divergent roles in initiation and progression","volume":"1","author":"Jambhekar","year":"2024","journal-title":"Blood Neoplasia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial cell dysfunction and the pathobiology of atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1007\/s40264-023-01345-w","article-title":"Challenges and opportunities in accessing and analysing FAERS data: a call towards a collaborative approach","volume":"46","author":"Giunchi","year":"2023","journal-title":"Drug Saf"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1643780\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:24:59Z","timestamp":1757568299000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1643780\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":20,"alternative-id":["10.3389\/fmed.2025.1643780"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1643780","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"article-number":"1643780"}}